CohBar, Inc. Announces Voluntary Delisting from the TSX Venture Exchange
Common stock will continue to trade on the Nasdaq Capital Market
MENLO PARK, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) and (TSXV:COB.U) (“CohBar” or the “Company”) today announced that it has applied to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”).
The Company decided to voluntarily delist from the TSXV because the limited trading activity in the Company’s shares no longer justifies the financial and administrative costs required to maintain a dual listing.
The Company’s common stock will continue to be listed on the Nasdaq Capital Market under its current symbol “CWBR”. The Company’s Canadian shareholders may trade in CohBar’s common stock through their brokers on that exchange.
CohBar is an innovative biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including obesity, nonalcoholic steatohepatitis (NASH), Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 100 MDPs.
About CohBar’s Lead Program
CohBar’s lead preclinical development program is based on MOTS-c, a mitochondrial-derived peptide discovered in 2012 by the Company’s founders and their academic collaborators, whose research has shown that MOTS-c plays a significant role in the regulation of metabolism. The Company has developed a novel, improved analog of the MOTS-c peptide, CB4211, which has demonstrated significant therapeutic potential in preclinical models of obesity and nonalcoholic steatohepatitis (NASH).
For additional company information, please visit www.cohbar.com.
This news release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking statements include statements regarding future trading of the Company’s Shares and its intention to delist from the TSX Venture Exchange. Forward-looking statements are based on current expectations, estimates and projections that involve a number of risks and uncertainties, including any the risk that Canadian shareholders may have difficulty accessing Nasdaq trading. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at www.sec.gov or www.sedar.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Investor and Media Contact:
Jeff Biunno, Chief Financial Officer
(650) 446-7888, Option 3
Released April 18, 2018